Table 20.
Clinical trials of the combination therapy of FGFR blockade and immune checkpoint inhibitor
| FGFR inhibitor | NCT number | Cancer types | Combination partners | Phase | Status |
|---|---|---|---|---|---|
| Pemigatinib | NCT05913661 | Intrahepatic Cholangiocarcinoma | PD-1 Inhibitors | II | Recruiting |
| NCT05004974 | NSCLC | Sintilimab | II | Recruiting | |
| NCT04949191 | Solid Tumors | Pembrolizumab | II | Active, not recruiting | |
| NCT04003610 | Urothelial Carcinoma | Pembrolizumab | II | Terminated | |
| NCT02393248 | Solid Tumors | Pembrolizumab | I/II | Terminated | |
| Futibatinib | NCT05945823 | Solid Tumors | Pembrolizumab and Chemotherapy | II | Recruiting |
| NCT05036681 | Microsatellite Stable Endometrial Carcinoma | Pembrolizumab | II | Recruiting | |
| NCT04828486 | Hepatocellular Carcinoma | Pembrolizumab | II | Recruiting | |
| NCT04601857 | Urothelial Cancer | Pembrolizumab | II | Recruiting | |
| Erdafitinib | NCT05564416 | Bladder Cancer | Atezolizumab | II | Withdrawn |
| Infigratinib | NCT05510427 | Cholangiocarcinoma | Atezolizumab and Bevacizumab | I | Withdrawn |
| HMPL-453 | NCT05173142 | Solid Tumors | Gemcitabine, Cisplatin, Toripalimab, and Docetaxel | I/II | Recruiting |
| Bemarituzumab | NCT05322577 | Gastric or Gastroesophageal Junction Cancer | CAPOX/SOX and Nivolumab | I | Recruiting |
| NCT05267470 | Squamous-Cell NSCLC | Pembrolizumab, Carboplatin and Paclitaxel/Nab-paclitaxel | I | Active, not recruiting | |
| NCT05111626 | Gastric or Gastroesophageal Junction Cancer | Chemotherapy (mFOLFOX6 or CAPOX) and Nivolumab | III | Recruiting |
Note: NSCLC non-small cell lung cancer